Andrew Smith, MD
Neurology · Fort Collins, CONPI 1053600072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,426 of the $34,859 with a category attached, or 90.2%. Sanofi accounts for 99.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $9,746 and has fallen 99.4% since, to $59 in 2025.
Across 28 payments — averaging $1244.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$35K
- TG Therapeutics, Inc.$59
- E.r. Squibb & Sons, L.L.C.$19
Across 17 payments — averaging $6460.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$63K
- Novartis$31K
- EMD Serono, Inc.$15K
What the payments were for
- Speaking & faculty fees$31,42690%
- Travel & lodging$2,4327%
- Food & beverage$9823%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 26 | $34,780 |
| TG Therapeutics, Inc. | 1 | $59 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUBAGIO$7,658
How this compares
$34,859 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GilenyaFingolimod Hcl | 15 | $149,044 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $113,411 |
| Kesimpta PenOfatumumab | 11 | $110,642 |
| FingolimodFingolimod Hcl | 51 | $72,570 |
| Dalfampridine ErDalfampridine | 71 | $24,433 |
| Glatiramer Acetate | 12 | $10,592 |
| Teriflunomide | 19 | $4,620 |
| Baclofen | 164 | $4,503 |
| Dimethyl Fumarate | 28 | $4,003 |
| Gabapentin | 189 | $3,503 |
| Acetazolamide | 17 | $3,122 |
| Oxcarbazepine | 15 | $1,918 |
| Pregabalin | 35 | $1,377 |
| Tizanidine Hcl | 61 | $1,024 |
| Levetiracetam | 25 | $809 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fort Collins
- Tamara MillerFort Collins$1.4M
- Timothy AllenFort Collins$31K
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
- Beverly GilderLone Tree$558K
- Michael AmentDenver$457K
- Enrique AlvarezAurora$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.